254 related articles for article (PubMed ID: 34998123)
1. Sculpting therapeutic monoclonal antibody N-glycans using endoglycosidases.
Trastoy B; Du JJ; García-Alija M; Li C; Klontz EH; Wang LX; Sundberg EJ; Guerin ME
Curr Opin Struct Biol; 2022 Feb; 72():248-259. PubMed ID: 34998123
[TBL] [Abstract][Full Text] [Related]
2. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody.
Giddens JP; Lomino JV; DiLillo DJ; Ravetch JV; Wang LX
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12023-12027. PubMed ID: 30397147
[TBL] [Abstract][Full Text] [Related]
3. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX
J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414
[TBL] [Abstract][Full Text] [Related]
4. A Method to Detect the Binding of Hyper-Glycosylated Fragment Crystallizable (Fc) Region of Human IgG1 to Glycan Receptors.
Blundell P; Pleass R
Methods Mol Biol; 2019; 1904():417-421. PubMed ID: 30539483
[TBL] [Abstract][Full Text] [Related]
5. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
6. Regulation of antibody effector functions through IgG Fc N-glycosylation.
Quast I; Peschke B; Lünemann JD
Cell Mol Life Sci; 2017 Mar; 74(5):837-847. PubMed ID: 27639381
[TBL] [Abstract][Full Text] [Related]
7. Structural insights into the mechanisms and specificities of IgG-active endoglycosidases.
Du JJ; Klontz EH; Guerin ME; Trastoy B; Sundberg EJ
Glycobiology; 2020 Mar; 30(4):268-279. PubMed ID: 31172182
[TBL] [Abstract][Full Text] [Related]
8. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
9. Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies.
Le NP; Bowden TA; Struwe WB; Crispin M
Biochim Biophys Acta; 2016 Aug; 1860(8):1655-68. PubMed ID: 27105835
[TBL] [Abstract][Full Text] [Related]
10. CD16a with oligomannose-type
Subedi GP; Barb AW
J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
[TBL] [Abstract][Full Text] [Related]
11. Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.
Li W; Zhu Z; Chen W; Feng Y; Dimitrov DS
Front Immunol; 2017; 8():1554. PubMed ID: 29181010
[TBL] [Abstract][Full Text] [Related]
12. Functional Role of Carbohydrate Residues in Human Immunoglobulin G and Therapeutic Monoclonal Antibodies.
Dorokhov YL; Sheshukova EV; Kosobokova EN; Shindyapina AV; Kosorukov VS; Komarova TV
Biochemistry (Mosc); 2016 Aug; 81(8):835-57. PubMed ID: 27677552
[TBL] [Abstract][Full Text] [Related]
13. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.
Hills AE; Patel A; Boyd P; James DC
Biotechnol Bioeng; 2001 Oct; 75(2):239-51. PubMed ID: 11536148
[TBL] [Abstract][Full Text] [Related]
14. Glycoform-resolved FcɣRIIIa affinity chromatography-mass spectrometry.
Lippold S; Nicolardi S; Domínguez-Vega E; Heidenreich AK; Vidarsson G; Reusch D; Haberger M; Wuhrer M; Falck D
MAbs; 2019 Oct; 11(7):1191-1196. PubMed ID: 31276431
[TBL] [Abstract][Full Text] [Related]
15. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
[TBL] [Abstract][Full Text] [Related]
16. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins.
Ahmed AA; Giddens J; Pincetic A; Lomino JV; Ravetch JV; Wang LX; Bjorkman PJ
J Mol Biol; 2014 Sep; 426(18):3166-3179. PubMed ID: 25036289
[TBL] [Abstract][Full Text] [Related]
17. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
18. The IgG-specific endoglycosidases EndoS and EndoS2 are distinguished by conformation and antibody recognition.
Sudol ASL; Crispin M; Tews I
J Biol Chem; 2024 May; 300(5):107245. PubMed ID: 38569940
[TBL] [Abstract][Full Text] [Related]
19. Assessing Fc glycan heterogeneity of therapeutic recombinant monoclonal antibodies using NP-HPLC.
Raju TS
Methods Mol Biol; 2013; 988():169-80. PubMed ID: 23475719
[TBL] [Abstract][Full Text] [Related]
20. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans.
Goetze AM; Liu YD; Zhang Z; Shah B; Lee E; Bondarenko PV; Flynn GC
Glycobiology; 2011 Jul; 21(7):949-59. PubMed ID: 21421994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
